Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
Date:11/10/2010

//www.scolr.com/.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning anticipated sales of our nutritional products and the timing thereof, the timing of anticipated shipment of our nutritional products, our expectations concerning conduct of the actual use study for our ibuprofen product, our expectations concerning regulatory approval of our pseudoephedrine product and the anticipated timing of such approval. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including lower than expected demand by national retailers for our nutritional products, our ability to conform to the sales planning cycles of the retailers targeted as potential customers for our nutritional products, constraints on our liquidity related to the greater working capital requirements of our nutritional business, unanticipated changes in the timing or amount of orders for our nutritional products, unanticipated problems or delays with our regulatory applications, unanticipated costs and expenses associated with our product development, clinical activities and regulatory review,  reductions in our royalty revenues, our ability to create and maintain partnerships or other relationships, the continuation of arrangements with our product development partners, customers and clinical project services providers, competition, government regulation and general economic conditions. For example, if we are not able to meet the timing and other expectations of the retailers we have targeted as potential customers of our nutritional products, we may not be able to generate revenue from sales of these
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
2. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
3. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
4. SCOLR Pharma, Inc. Licenses Dietary Supplements
5. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
6. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
7. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
8. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
9. Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition
10. Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition
11. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
(Date:9/23/2014)... 2014  MEDIMETRIKS PHARMACEUTICALS today announced that ... have been elected to Medimetriks, Board of Directors ... who will serve on Medimetriks, Audit Committee, brings ... the Company.  Mr. Lary is currently Managing Director, ... institutional investment firm.  Mr. Lary is responsible for ...
(Date:9/23/2014)... 23, 2014  Vesselon, Inc. today announced the appointment ... effective September 15, 2014. Dr. Raths, appointment follows Vesselon,s ... agent to market a private preferred Series A round ... treatment. "Jurgen,s deep experience across multiple functional ... asset to Vesselon as we develop our device that ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
(Date:9/23/2014)... 2014 SOURCE: Solutions from Our ... were made to Rimidi Diabetes and ... with business solutions to challenges faced by patients and ... collaboration between The Hitachi Foundation, Village ... entrepreneurs with the investment capital, mentoring, and support needed ...
(Date:9/23/2014)... Risperdal lawsuits ( http://www.drugbot.com/risperdal/lawsuit/ ) continue ... Liebhard LLP reports. According to an Order issued in ... 19th, the Court has dismissed fraud and negligence per ... on behalf of a man who allegedly developed gynecomastia ... use of Risperdal. In dismissing the Plaintiff’s negligence per ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- The ... million in additional funding in scientific trials to ... and clinical studies. The supplemental monies were ... fields, including basic immunology, cardiovascular physiology, neural circuitry, ... Sept. 23. "This funding strategy demonstrates our ...
(Date:9/23/2014)... They are common suggestions to remedy stress: You just ... out and see people. , Turns out all ... a lot better a new large scale study ... depression, less perceived stress and enhanced mental health and well-being, ... with partners from De Montfort University, James Hutton Institute, and ...
(Date:9/23/2014)... that you may want to get screened and treated ... knife. According to a first-of-its-kind study in the ... journal of the American Society of Anesthesiologists (ASA), patients ... condition prior to surgery are less likely to develop ... , "OSA is a common disorder that affects millions ...
Breaking Medicine News(10 mins):Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 5Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 3Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:Beating stress outdoors? Nature group walks may improve mental health 2Health News:New research suggests sleep apnea screening before surgery 2
... their families to take the following steps:, , ... When you are sick, keep your distance from others to protect them from ... you are sick to help prevent others from catching your illness. Cover your ... and nose with a tissue when coughing or sneezing. It may prevent those ...
... The following is a joint statement from Bruce Yarwood, ... and National Center for Assisted Living (AHCA/NCAL), and Alan ... Home Care: We commend Senators Baucus and Grassley for ... health care policy reforms that will impact every American ...
... April 29 Pennsylvania,s chief agriculture and ... improve national and state food safety initiatives at the ... in Harrisburg. Agriculture Secretary Dennis Wolff and Health Secretary ... in protecting the food supply and responding to outbreaks, ...
... Almost half of those in ICU had deficient levels, study ... levels are deficient in many critically ill patients, new research ... almost half of people in an intensive care unit were ... to be common in seriously ill patients," said study author ...
... PALO ALTO, Calif., April 29 Varian Medical Systems ... from continuing operations of $0.64 per diluted share in ... earnings from continuing operations of $0.57 per diluted share ... research instruments operation, net earnings per diluted share in ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today ... first quarter ended March 31, 2009, Sangamo reported a consolidated ... to a net loss of $8.0 million, or $0.20 per ... 31, 2009, the company had cash and cash equivalents, marketable ...
Cached Medicine News:Health News:Workforce Swine Flu Pandemic Survival Preparedness Tips For Business 2Health News:National Long Term Care Leaders Praise Overall Baucus Health Reform Effort, Express Specific Concerns Moving Forward 2Health News:Pennsylvania Governor's Food Safety Council Meets to Discuss Food Supply Protection 2Health News:Critically Ill Patients Lack Vitamin D 2Health News:Critically Ill Patients Lack Vitamin D 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 2Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 4Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 5Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 6Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 7Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 8Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 9Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 2Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 3Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 4Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 5Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 6Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 7
Bone Curette, 145 mm...
Kevorkian Collector Endocervical Curette is a stainless-steel curette with rounded tip....
Cobb Curettes, 11 inches...
...
Medicine Products: